Patient death in Brazil not related to Elevidys, Sarepta says

The US Food and Drug Administration (FDA) issued a press release late Friday announcing an investigation into the death of an eight-year-old Duchenne muscular dystrophy (Duchenne) patient who had apparently received Elevidys (delandistrogene moxeparvovec) gene therapy.

However, Sarepta (Nasdaq: SRPT)—the US biotech behind Elevidys—has since stressed that the death of this patient was deemed unrelated to treatment with the drug, which has been associated with other fatalities in recent weeks, prompting a pause in shipments in the USA and certain other markets.